Editorial: Cell-based Therapies for Stroke: Promising Solution or Dead End?

Stem Cell-Based Therapies for Ischemic Stroke

In recent years, stem cell-based approaches have attracted more attention from scientists and clinicians due to their possible therapeutical effect on stroke. Animal studies have demonstrated that the beneficial effects of stem cells including embryonic stem cells (ESCs), inducible pluripotent stem cells (iPSCs), neural stem cells (NSCs), and mesenchymal stem cell (MSCs) might be due to cell re...

Editorial: Pursuing efficiency: a dead end for HTA?

Editorial: Cell-Based Therapies for Diabetic Microvascular Complications

There is an alarming increase in the number of cases of diabetes with the global prevalence rate at 9% for the year 2014 (1). Around 387 million patients worldwide are suffering from diabetes, and this number is expected to increase by 50% by 2030 (2). In particular, the South East Asian countries are affected most due to diabetes with projected 10% increase in diabetic patients by 2035 (3). Di...

Erythropoietin for stroke treatment: dead or alive?

Endothelial progenitor cell (EPC) mobilization from the bone marrow was considered to improve outcome after ischemic stroke. Erythropoietin (EPO) might be a potential candidate stroke drug that increases the number of circulating EPCs. In the previous issue of Critical Care, Yip and colleagues investigated the effect of EPO in stroke patients on both clinical outcome and EPC stimulation. Althou...

Neural Stem Cells: Exogenous and Endogenous Promising Therapies for Stroke

M. Guerra-Crespo1,2, A.K. De la Herrán-Arita1, A. Boronat-García1, G. Maya-Espinosa1, J.R. García-Montes1, J.H. Fallon3 and R. Drucker-Colín1,2 1Departamento de Neuropatología Molecular, Instituto de Fisiología Celular 2 Grupo Células Troncales Adultas, Regeneración Neuronal y Enfermedad de Parkinson Universidad Nacional Autónoma de México 3Department of Psychiatry and Human Behavior, Universit...